Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed metastatic solid tumor
• Disease progressed during at least one standard therapy OR has a disease for which there is no standard therapy
• No squamous cell carcinoma of the lung
• Asymptomatic brain metastases allowed provided both of the following criteria are met:
• Brain metastases were treated ≥ 6 months ago
• Brain metastases are clinically stable without steroid treatment for 1 week
• No clinically relevant pleural effusions or ascites that cannot be controlled by drainage (group 2)

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Hemoglobin ≥ 9.0 g/dL
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN
• INR < 1.5 or PT/PTT normal
• Creatinine clearance ≥ 45 mL/min
• Negative serum pregnancy test
• Fertile patients must use effective contraception during and for at least 2 weeks after completion of study treatment
• No New York Heart Association class III or IV congestive heart failure
• No unstable angina (anginal symptoms at rest) or new onset angina (within the past 3 months)
• No myocardial infarction within the past 6 months
• No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
• No uncontrolled hypertension, defined as systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg, despite optimal medical management
• No known severe hypersensitivity to sorafenib tosylate or any its excipients, etoposide, pemetrexed disodium, cisplatin, or carboplatin
• No known HIV infection
• No chronic hepatitis B or C
• No active clinically serious infection > CTCAE grade 2
• No thrombotic or embolic events, such as cerebrovascular accident or transient ischemic attacks, within the past 6 months
• No pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks
• No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks
• No serious non-healing wound, ulcer, or bone fracture
• No evidence or history of bleeding diathesis or coagulopathy
• No condition that impairs the patient's ability to swallow whole pills
• No malabsorption problem, uncontrolled inflammatory bowel disease, or gastrointestinal disorder causing ≥ 5 bowel movements in a 24-hour period
• No significant traumatic injury within the past 4 weeks
• Able to take vitamin B12 supplementation and folic acid (group 2)

PRIOR CONCURRENT THERAPY:

• More than 4 weeks since prior major surgery or open biopsy
• No more than 3 prior cytotoxic therapies for metastatic disease
• No concurrent St. John's wort or rifampin
• No non-steroidal anti-inflammatory drugs (NSAIDs) for 2 days before (5 days for long-acting NSAIDs), during, and for 2 days after pemetrexed disodium administration (group 2)
• Concurrent anticoagulation treatment with warfarin or heparin allowed